Shanghai Haoyuan Chemexpress Co Ltd. Stock Analysis 688131.SS

Shanghai Haoyuan Chemexpress Co. Ltd. engages in the small molecule drug research & development services and industrial application. The company is headquartered in Shanghai, Shanghai and currently employs 4,195 full-time employees. The company went IPO on 2021-06-08. The molecular building blocks, tool compounds and biochemical reagents business mainly provides milligram to kilogram products and technical services in the drug discovery stage. The active pharmaceutical ingredient and intermediate business products cover anti-tumor, anti-infection, diabetes, cardiovascular and cerebrovascular disease treatment, immune system, nervous system, digestion and other fields. The preparation production business provides customers with pharmaceutical research, registration and production services for preparations. The firm mainly conducts its businesses in the domestic and foreign markets.